,text,position,name,last,events,dateString,collapsed,checked
0,"<p>New funding applications are referred to one of Pharmac's Funding Application Advisors (FAAs), who'll review the application to ensure they have the relevant information to undertake a preliminary analysis.&nbsp; They may seek more information if required.</p>
<p><a class=""external-link"" href=""https://www.pharmac.govt.nz/medicines/how-medicines-are-funded/new-funding-applications/"" rel=""nofollow"">https://www.pharmac.govt.nz/medicines/how-medicines-are-funded/new-funding-applications/</a></p>",0,Application Received,False,"[{'Summary': {'s': None, 'fs': None, 'change': None}, 'Published_Recommendation': {'s': None, 'fs': None, 'change': None}, 'Published_Discussion': {'s': None, 'fs': None, 'change': None}, 'Published_Application': {'s': None, 'fs': None, 'change': None}, 'PTAC_Comments': {'s': None, 'fs': None, 'change': None}, 'Outcome': {'s': None, 'fs': None, 'change': None}, 'Links': {'s': None, 'fs': None, 'change': None}, 'Formatted_Date': {'s': 'Feb 2023', 'fs': 'Feb 2023', 'change': None}, 'Event_Description': {'s': 'Application received', 'fs': 'Application received', 'change': None}, 'e': {'attributes': {'type': 'Application_Event__c', 'url': '/services/data/v65.0/sobjects/Application_Event__c/a0POZ000009Dz0t2AC'}, 'Id': 'a0POZ000009Dz0t2AC', 'Event_Date__c': '2023-02-17', 'Event_Description__c': 'Application received', 'Stage__c': 'Application Received', 'Formatted_Date__c': 'Feb 2023', 'Status_History__c': 'a13OZ000001KCakYAG'}, 'change': None}]",Feb 2023,False,True
1,"<p>Pharmac is identifying and gathering information required to get clinical advice.  The <a class=""external-link"" href=""https://pharmac.govt.nz/about/expert-advice/pharmacology-and-therapeutics-advisory-committee-ptac/"" rel=""nofollow"">Pharmacology and Therapeutics Advisory Committee (PTAC)</a>  meets quarterly. There are also around 20 expert <a class=""external-link"" href=""https://pharmac.govt.nz/about/expert-advice/specialist-advisory-committees/"" rel=""nofollow"">Specialist Advisory Committees (SACs)</a>, previously expert Subcommittees, which provide clinical evaluations in specialist areas. Specialist Advisory Committees meet as required to discuss issues referred to them by PTAC or Pharmac.</p>
<p style=""height: 20px"">&nbsp;</p>
<p>In November 2021, we introduced separate terms of reference for the SACs to make clear that these committees have different, but complementary, roles, expertise and perspectives to PTAC.</p>
<p style=""height: 15px"">&nbsp;</p>
<p>PTAC and SACs may make recommendations to Pharmac that differ from each other when looking at the same evidence. Pharmac considers the recommendations provided by all our clinical advisory committees when assessing applications.</p>
<p style=""height: 20px"">&nbsp;</p>
<p><a class=""external-link"" href=""https://pharmac.govt.nz/about/expert-advice/pharmacology-and-therapeutics-advisory-committee-ptac/ptac-terms-of-reference-july-2021/"" rel=""nofollow"">PTAC</a>  and <a class=""external-link"" href=""https://pharmac.govt.nz/about/expert-advice/specialist-advisory-committees/specialist-advisory-committee-terms-of-reference//"" rel=""nofollow"">Specialist Advisory Committees</a> records of the meeting will be published on this website in accordance with the Terms of Reference.</p>",1,Seeking Clinical Advice,False,"[{'Summary': {'s': None, 'fs': None, 'change': None}, 'Published_Recommendation': {'s': None, 'fs': None, 'change': None}, 'Published_Discussion': {'s': None, 'fs': None, 'change': None}, 'Published_Application': {'s': None, 'fs': None, 'change': None}, 'PTAC_Comments': {'s': None, 'fs': None, 'change': None}, 'Outcome': {'s': None, 'fs': None, 'change': None}, 'Links': {'s': None, 'fs': None, 'change': None}, 'Formatted_Date': {'s': 'Feb 2023', 'fs': 'Feb 2023', 'change': None}, 'Event_Description': {'s': 'Clinical advice required', 'fs': 'Clinical advice required', 'change': None}, 'e': {'attributes': {'type': 'Application_Event__c', 'url': '/services/data/v65.0/sobjects/Application_Event__c/a0POZ000009Dz0u2AC'}, 'Id': 'a0POZ000009Dz0u2AC', 'Event_Date__c': '2023-02-28', 'Event_Description__c': 'Clinical advice required', 'Stage__c': 'Seeking Clinical Advice', 'Formatted_Date__c': 'Feb 2023', 'Status_History__c': 'a13OZ000001KDAFYA4'}, 'change': None}, {'Summary': {'s': None, 'fs': None, 'change': None}, 'Published_Recommendation': {'s': None, 'fs': None, 'change': None}, 'Published_Discussion': {'s': None, 'fs': None, 'change': None}, 'Published_Application': {'s': None, 'fs': None, 'change': None}, 'PTAC_Comments': {'s': None, 'fs': None, 'change': None}, 'Outcome': {'s': None, 'fs': None, 'change': None}, 'Links': {'s': None, 'fs': None, 'change': None}, 'Formatted_Date': {'s': 'Feb 2023', 'fs': 'Feb 2023', 'change': None}, 'Event_Description': {'s': 'Assigned to Rare Disorders Advisory Committee meeting to provide advice on Tuesday 7 March 2023', 'fs': 'Assigned to Rare Disorders Advisory Committee meeting to provide advice on Tuesday 7 March 2023', 'change': None}, 'e': {'attributes': {'type': 'Application_Event__c', 'url': '/services/data/v65.0/sobjects/Application_Event__c/a0POZ000009Dz0v2AC'}, 'Id': 'a0POZ000009Dz0v2AC', 'Event_Date__c': '2023-02-28', 'Event_Description__c': 'Assigned to Rare Disorders Advisory Committee meeting to provide advice on Tuesday 7 March 2023', 'Stage__c': 'Seeking Clinical Advice', 'Formatted_Date__c': 'Feb 2023', 'Status_History__c': 'a13OZ000001K6K7YAK'}, 'change': None}, {'Summary': {'s': None, 'fs': None, 'change': None}, 'Published_Recommendation': {'s': '<p>1.1.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0</span>The Advisory Committees <strong>recommended</strong> that the funded access to nusinersen and/or risdiplam be widened to include SMA types IIIb, IIIc and undefined type III within the context of treatments for rare disorders and for neurological disorders with a <strong>high priority</strong> subject to the following Special Authority criteria (changes marked from current funded criteria):</p><p><br></p><p class=""ql-indent-1""><span style=""font-size: 9pt;"">Initial application from any relevant practitioner. Approvals valid for 12 months for applications meeting the following:</span></p><p class=""ql-indent-1""><span style=""font-size: 9pt;"">All of the following:</span></p><p class=""ql-indent-2""><span style=""font-size: 9pt;"">1</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0</span><span style=""font-size: 9pt;"">Person has genetic documentation of a homozygous </span><em style=""font-size: 9pt;"">SMN1</em><span style=""font-size: 9pt;""> gene deletion, homozygous </span><em style=""font-size: 9pt;"">SMN1</em><span style=""font-size: 9pt;""> point mutation, or compound heterozygous mutation; and</span></p><p class=""ql-indent-2""><span style=""font-size: 9pt;"">2</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0</span><span style=""font-size: 9pt;"">Person is 18 years of age or under; and</span></p><p class=""ql-indent-2""><span style=""font-size: 9pt;"">3</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0</span><span style=""font-size: 9pt;"">Either</span></p><p class=""ql-indent-3""><span style=""font-size: 9pt;"">3.1</span><span style=""font-size: 7pt;"">\xa0\xa0</span><span style=""font-size: 9pt;"">Person has experienced the defined signs and symptoms of SMA type I, II or III</span><strike style=""font-size: 9pt;"">a prior to three years of age</strike><span style=""font-size: 9pt;"">; or</span></p><p class=""ql-indent-3""><span style=""font-size: 9pt;"">3.2</span><span style=""font-size: 7pt;"">\xa0\xa0</span><span style=""font-size: 9pt;"">Both:</span></p><p class=""ql-indent-4""><span style=""font-size: 9pt;"">3.2.1</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0</span><span style=""font-size: 9pt;"">Person is pre-symptomatic; and</span></p><p class=""ql-indent-4""><span style=""font-size: 12px;"">3.2.2\xa0\xa0\xa0\xa0\xa0</span><span style=""font-size: 9pt;"">Person has three or less copies of SMN2.</span></p><p class=""ql-indent-1""><span style=""font-size: 9pt;"">\xa0</span></p><p class=""ql-indent-1""><span style=""font-size: 9pt;"">Renewal from any relevant practitioner. Renewals valid for 12 months. All of the following:</span></p><p class=""ql-indent-2""><span style=""font-size: 9pt;"">1</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0</span><span style=""font-size: 9pt;"">There has been demonstrated maintenance of motor milestone function since treatment initiation; and</span></p><p class=""ql-indent-2""><span style=""font-size: 9pt;"">2</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0</span><span style=""font-size: 9pt;"">Person does not require invasive permanent ventilation (at least 16 hours per day), in the absence of a potentially reversible cause while being treated with nusinersen; and</span></p><p class=""ql-indent-2""><span style=""font-size: 9pt;"">3</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0</span><strike style=""font-size: 9pt;"">Nusinersen </strike><strong style=""font-size: 9pt;"">N</strong><strike style=""font-size: 9pt;"">n</strike><span style=""font-size: 9pt;"">ot to be administered in combination with other SMA disease modifying treatments or gene therapy.</span></p><p class=""ql-indent-1""><span style=""font-size: 9pt;"">\xa0</span></p><p>1.2.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0</span>In making this recommendation the Committees considered:</p><p class=""ql-indent-1""><span style=""font-family: Symbol;"">·</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The high unmet health need of people with SMA type III;</p><p class=""ql-indent-1""><span style=""font-family: Symbol;"">·</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The overlap in health need between people with SMA type IIIa and types IIIb and IIIc;</p><p class=""ql-indent-1""><span style=""font-family: Symbol;"">·</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>While the SUNFISH trial did not include stratified results for type IIIb and IIIc individuals, there was sufficient evidence to show that there was treatment benefit for adults with SMA types II and III in the form of maintaining physical function</p>', 'fs': '<p>1.1.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0</span>The Advisory Committees <strong>recommended</strong> that the funded access to nusinersen and/or risdiplam be widened to include SMA types IIIb, IIIc and undefined type III within the context of treatments for rare disorders and for neurological disorders with a <strong>high priority</strong> subject to the following Special Authority criteria (changes marked from current funded criteria):</p><p><br></p><p class=""ql-indent-1""><span style=""font-size: 9pt;"">Initial application from any relevant practitioner. Approvals valid for 12 months for applications meeting the following:</span></p><p class=""ql-indent-1""><span style=""font-size: 9pt;"">All of the following:</span></p><p class=""ql-indent-2""><span style=""font-size: 9pt;"">1</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0</span><span style=""font-size: 9pt;"">Person has genetic documentation of a homozygous </span><em style=""font-size: 9pt;"">SMN1</em><span style=""font-size: 9pt;""> gene deletion, homozygous </span><em style=""font-size: 9pt;"">SMN1</em><span style=""font-size: 9pt;""> point mutation, or compound heterozygous mutation; and</span></p><p class=""ql-indent-2""><span style=""font-size: 9pt;"">2</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0</span><span style=""font-size: 9pt;"">Person is 18 years of age or under; and</span></p><p class=""ql-indent-2""><span style=""font-size: 9pt;"">3</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0</span><span style=""font-size: 9pt;"">Either</span></p><p class=""ql-indent-3""><span style=""font-size: 9pt;"">3.1</span><span style=""font-size: 7pt;"">\xa0\xa0</span><span style=""font-size: 9pt;"">Person has experienced the defined signs and symptoms of SMA type I, II or III</span><strike style=""font-size: 9pt;"">a prior to three years of age</strike><span style=""font-size: 9pt;"">; or</span></p><p class=""ql-indent-3""><span style=""font-size: 9pt;"">3.2</span><span style=""font-size: 7pt;"">\xa0\xa0</span><span style=""font-size: 9pt;"">Both:</span></p><p class=""ql-indent-4""><span style=""font-size: 9pt;"">3.2.1</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0</span><span style=""font-size: 9pt;"">Person is pre-symptomatic; and</span></p><p class=""ql-indent-4""><span style=""font-size: 12px;"">3.2.2\xa0\xa0\xa0\xa0\xa0</span><span style=""font-size: 9pt;"">Person has three or less copies of SMN2.</span></p><p class=""ql-indent-1""><span style=""font-size: 9pt;"">\xa0</span></p><p class=""ql-indent-1""><span style=""font-size: 9pt;"">Renewal from any relevant practitioner. Renewals valid for 12 months. All of the following:</span></p><p class=""ql-indent-2""><span style=""font-size: 9pt;"">1</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0</span><span style=""font-size: 9pt;"">There has been demonstrated maintenance of motor milestone function since treatment initiation; and</span></p><p class=""ql-indent-2""><span style=""font-size: 9pt;"">2</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0</span><span style=""font-size: 9pt;"">Person does not require invasive permanent ventilation (at least 16 hours per day), in the absence of a potentially reversible cause while being treated with nusinersen; and</span></p><p class=""ql-indent-2""><span style=""font-size: 9pt;"">3</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0</span><strike style=""font-size: 9pt;"">Nusinersen </strike><strong style=""font-size: 9pt;"">N</strong><strike style=""font-size: 9pt;"">n</strike><span style=""font-size: 9pt;"">ot to be administered in combination with other SMA disease modifying treatments or gene therapy.</span></p><p class=""ql-indent-1""><span style=""font-size: 9pt;"">\xa0</span></p><p>1.2.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0</span>In making this recommendation the Committees considered:</p><p class=""ql-indent-1""><span style=""font-family: Symbol;"">·</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The high unmet health need of people with SMA type III;</p><p class=""ql-indent-1""><span style=""font-family: Symbol;"">·</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The overlap in health need between people with SMA type IIIa and types IIIb and IIIc;</p><p class=""ql-indent-1""><span style=""font-family: Symbol;"">·</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>While the SUNFISH trial did not include stratified results for type IIIb and IIIc individuals, there was sufficient evidence to show that there was treatment benefit for adults with SMA types II and III in the form of maintaining physical function</p>', 'change': None}, 'Published_Discussion': {'s': '<h3><em>Patient lived experience</em></h3><p>1.1.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0</span>A New Zealander with SMA who had recently moved to Australia to access funded treatment and a clinician treating SMA with nusinersen and risdiplam in Australia shared their experiences with the Rare Disorders Advisory Committee, Neurological Committee observers and Pharmac staff. The Committees and Pharmac staff valued this opportunity and considered that it helped to frame the Committees’ discussions about treatment of SMA in adults with a different perspective.</p><p>1.2.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0</span>The person with SMA described the losses experienced due to SMA as a cumulative trauma that is constantly affecting their life. They recounted the difficult decision to move from New Zealand in order to access funded treatment, and how their family had to sacrifice being near their support network for this purpose. </p><p>1.3.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0</span>The person described how commencing treatment with nusinersen as an adult had positively impacted their life. They recounted that since receiving treatment they were able to stand stronger, walk further and complete tasks that they had previously lost the ability to do due to SMA symptoms. They described how treatment offered a better life for them, their family, and the economy as they had increased ability to work.\xa0</p><p>1.4.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0</span>The clinician treating SMA in adults described how they had observed stabilisation or improvements of SMA symptoms in almost all people they had treated with nusinersen or risdiplam. They recounted that the people they treated shared treatment expectations of stabilisation and maintaining independence, with anything more being experienced as a bonus. </p><p>1.5.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0</span>Both the individual with SMA, and the clinician emphasised that the benefits of treatment with nusinersen or risdiplam should not be underestimated, as even small benefits could make significant differences to people&#39;s lives. </p><h3><em>Māori impact</em></h3><p>1.6.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committees discussed the impact of funding nusinersen and risdiplam for SMA groups currently under consideration on Māori health areas of focus and Māori health outcomes. The Committees noted unpublished 2023 reporting by Richard Roxburgh and colleagues of the prevalence of SMA in Māori people being approximately 0.34/100,000 live births and corresponding incidence 1.7/100,000 live births (95% CI 0 to 9.3).</p><p>1.7.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committees noted that SMA is not included as a Māori health area of focus in Te Pātaka Whaioranga - Pharmac’s Māori responsiveness strategy.</p><h3><em>Background</em></h3><p>1.8.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committees noted that from 1 January 2023, nusinersen has been funded for people aged 18 years and under with pre-symptomatic SMA or symptomatic SMA types I, II or IIIa. The Committees noted that Pharmac has recently consulted on a proposal to fund risdiplam from 1 May 2023 with the same access criteria as nusinersen.</p><p>1.9.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committees noted that substantive feedback was received in response to Pharmac’s consultation to fund nusinersen and risdiplam, regarding access criteria. The Committees noted that consultation responses included feedback that treatments should be funded for all people with SMA, including those who start treatment after 18 years of age with the types otherwise eligible within the currently proposed criteria, and for individuals with SMA types IIIb, IIIc and IV.</p><p>1.10.<span style=""font-size: 7pt;"">\xa0\xa0\xa0</span>The current eligibility criteria reflect the population requested in the funding application, the people identified by our clinical advisors as having the highest unmet health need and the most potential to benefit from treatment and aligns with the clinical trial evidence that was considered by our clinical advisors at the time. More information can be found in the Application Tracker record for nusinersen (for <a href=""https://connect.pharmac.govt.nz/apptracker/s/application-public/a102P000008puSr/p001050"" target=""_blank"">SMA types I II and III</a> and <a href=""https://connect.pharmac.govt.nz/apptracker/s/application-public/a102P000009QXCv/p001488"" target=""_blank"">pre-symptomatic SMA</a>).</p><h3><em>Health Need</em></h3><p>1.11.<span style=""font-size: 7pt;"">\xa0\xa0\xa0</span>The Committees noted that the incidence of SMA in New Zealand is approximately 0.8/10,000 live births, equating to approximately 4-5 incident cases of SMA per year as per an unpublished study by Rodrigues et al (2021). The Committees noted that the unpublished publication described the current prevalence of SMA in New Zealand as 1.7/100,000 people, or approximately 80 people in total.</p><p>1.12.<span style=""font-size: 7pt;"">\xa0\xa0\xa0</span>The Committees noted that the unpublished article by Rodrigues et al which stated that epidemiological studies suggest that 50-60% of incident SMA cases are SMA type 1, however due to the short life expectancy SMA type 1 is less prevalent than other forms.\xa0</p><p>1.13.<span style=""font-size: 7pt;"">\xa0\xa0\xa0</span>The Committees noted that SMA presents as a spectrum disease, and that there can be overlap in symptom severity between types. Members noted that the types of SMA are largely defined by the time of symptom onset, but also that there is an inverse correlation between severity and SMN2 copy number. The Committees noted that treatment in the pre-symptomatic setting is based on SMN2 copy number, as symptoms have not yet developed. </p><p>1.14.<span style=""font-size: 7pt;"">\xa0\xa0\xa0</span>The Committees noted data from the New Zealand SMA registry reporting that around 40 individuals on the registry were over 18 years of age as of 1 March 2023. The Committees noted that due to the voluntary nature of the registry, all people may not be included.</p><p>1.15.<span style=""font-size: 7pt;"">\xa0\xa0\xa0</span>The Committees noted that individuals who are pre-symptomatic are unable to be classified as type I, II, III or IV, which are defined based on time of symptom onset; and so are classified by the number of SMN2 copies, due to current evidence indicating that number of SMN2 copies correlating inversely with disease severity.</p><p><br></p><h4><span style=""font-family: Arial, sans-serif; font-size: 11pt;"">Type IIIb, III c and undefined III:</span></h4><p>1.16.<span style=""font-size: 7pt;"">\xa0\xa0\xa0</span>The Committees noted that individuals with SMA type III typically develop the ability to walk without assistance and have an unaffected life expectancy, however the Committees recognised that there are a range of mobility limitations ranging from abnormal gait caused by weakness in their hip and/or thigh muscles to loss of ambulation during adolescence or adulthood. In some patients, there may be considerable burden of disease with reduced employment, higher health needs, and psychological impacts that may be present for much of the individual’s adult life. The Committees considered that the impact of SMA over time for people with SMA type IIIb should not be underestimated, noting that they may lose ambulation and require a wheelchair later in life.</p><p>1.17.<span style=""font-size: 7pt;"">\xa0\xa0\xa0</span>The Committees considered that all individuals with SMA type III represent a high proportion of the prevalent population (given lower to low survival rates in types I and II). The Committees considered that individuals with type IIIa were less likely to be walking at 10 years of age than those with SMA type IIIb. The Committees considered that individuals with type IIIa may have similar orthopaedic surgery needs to individuals with SMA type II, whereas individuals with type IIIb usually reach normal early developmental milestones.</p><p>1.18.<span style=""font-size: 7pt;"">\xa0\xa0\xa0</span>The Committees considered that people aged 18 years and under with type IIIb, IIIc and undefined III had a high unmet health need. Members considered that at it can be difficult to differentiate between subtypes IIIa, b and c from due to phenotypic overlap and that this in part is likely explained by commonalities in SMN2 copy numbers.</p><p> </p><h4><span style=""font-family: Arial, sans-serif; font-size: 11pt;"">Adults with type II and III:</span></h4><p>1.19.<span style=""font-size: 7pt;"">\xa0\xa0\xa0</span>The Committees considered that people aged 19 years and over with SMA Type II and III SMA have high unmet health need. Members noted that adults with SMA, as with children with SMA, can experience substantial morbidity and in some cases early mortality. Members noted the impact of frequent medical appointments, hospital admissions, and reliance on carers. The Committees considered that SMA is a progressive disease, with symptoms gradually worsening over time, including the loss of ambulation.</p><p>1.20.<span style=""font-size: 7pt;"">\xa0\xa0\xa0</span>The Committees considered the health need of families and whānau of people with SMA is similarly high across subtypes and age. The Committees reiterated the comments from PTAC in August 2018; that there is a high health need for family, whānau, and caregivers of SMA patients, and that some families have left New Zealand to seek treatment internationally, such as moving to Australia to access funded treatment, in some cases leaving behind their families, whānau and support systems. The Committees considered that only those individuals belonging to households with the financial means to relocate can make the choice to move overseas, and that those living in more difficult socioeconomic circumstances would not have this option. \xa0</p><p><br></p><h4><span style=""font-family: Arial, sans-serif; font-size: 11pt;"">Type IV</span></h4><p>1.21.<span style=""font-size: 7pt;"">\xa0\xa0\xa0</span>The Committees considered that people with SMA type IV have a low health need compared with those with other SMA types. The Committees considered that the nature of SMA type IV symptoms is poorly defined. The Committees noted reports of individuals in their 20s to 40s being ambulant and requiring no respiratory support and/or maintaining a sedentary occupation (<a href=""https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4628728/"" target=""_blank"">Kolb et al. Neurol Clin 2015; 33:831</a>). The Committees considered that SMA type IV is a slow progressing form of SMA where limb weakness occurs gradually, and often without major motor impairments, respiratory impacts or changes to mortality. The Committees noted that the average age at symptom onset of SMA type IV is also poorly defined and that the subtype is broadly defined by individuals experiencing the onset of symptoms after the age of 18 years. The Committees noted that individuals with SMA type IV have a standard life expectancy.</p><p><br></p><h3><em>Health Benefit</em></h3><h4><span style=""font-family: Arial, sans-serif; font-size: 11pt;"">Nusinersen</span></h4><p>1.22.<span style=""font-size: 7pt;"">\xa0\xa0\xa0</span>The Committees noted results from an observational prospective longitudinal follow-up study which aimed to determine changes in motor and respiratory function after treatment with nusinersen in adults with SMA (<a href=""https://cp.neurology.org/content/11/3/e317"" target=""_blank"">Duong et al. Neurol Clin Pract. 2021;11(3):e317-e327</a>). The Committees considered that the study’s population most closely matched the population of individuals with SMA in New Zealand in regard to ambulation status. The Committees noted that individuals were treated for a mean treatment duration of 12.5 months. The Committees considered that some broad objective measures, including various motor and respiratory measures, reported stability rather than the expected decline, while some results reported a non-significant trend towards improvement. The Committees noted that outcomes were not analysed according to subtype of SMA. The Committees considered limitations of the study included that it was observational, non-randomised and, not blinded (but considered that blinded studies were now unlikely to be conducted), the short follow up period, possible selection bias, and imprecision with wide confidence intervals.\xa0</p><p>1.23.<span style=""font-size: 7pt;"">\xa0\xa0\xa0</span>The Committees noted a prospective three year SMArtCARE Registry-based observational longitudinal follow-up study that assessed improvements in walking distance during nusinersen treatment (<a href=""https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9881023/"" target=""_blank"">Pechmann et al. 2023;10(1):29-40</a>). The Committees noted that the study included adult as well as paediatric participants, all whom were walking independently at the start of the study. The Committees noted the mean age of SMA symptom onset was 11 years, and mean age at the start of treatment was 37 years. The Committees noted that 26% of adult participants experienced clinically meaningful improvement of equal to or more than 30 metres in the 6-minute walk time (6MWT) test at the last available visit (up to 38 months).</p><p>1.24.<span style=""font-size: 7pt;"">\xa0\xa0\xa0</span>The Committees also noted the following reviews:</p><p class=""ql-indent-1""><span style=""font-family: Symbol;"">·</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span><a href=""https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8515709/"" target=""_blank"">Coratti et </a><a href=""https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8515709/"" target=""_blank"" style=""color: windowtext;"">al</a><a href=""https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8515709/"" target=""_blank"">. Orphanet J Rare Dis. 2021;16(1):430</a></p><p class=""ql-indent-1""><span style=""font-family: Symbol;"">·</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span><a href=""https://pubmed.ncbi.nlm.nih.gov/35178673/"" target=""_blank"">Gavriilaki et al. Neurotherapeutics. 2022;19(2):464-75</a></p><p class=""ql-indent-1""><span style=""color: windowtext; font-family: Symbol;"">·</span><span style=""color: windowtext; font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span><a href=""https://pubmed.ncbi.nlm.nih.gov/35218574/"" target=""_blank"">Rad et al. Muscle Nerve. 2022;65(5):498-507</a></p><p class=""ql-indent-1""><span style=""font-family: Symbol;"">·</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span><a href=""https://www.ncbi.nlm.nih.gov/books/NBK566621/"" target=""_blank"">Janoudi et ak. Ottawa (ON): Canadian Agency for Drugs and Technologies in Health. 2020.</a></p><p>1.25<em>.</em><span style=""font-size: 7pt;"">\xa0\xa0\xa0</span>Committee noted results from <a href=""https://pubmed.ncbi.nlm.nih.gov/31019106/"" target=""_blank"">Darras et al. Neurology. 2019;92(21):e2492-e2506</a>, a phase 1b/2a study which followed 28 children with SMA, 18 of whom had type III disease. All motor outcomes improved over the 715 day extension arm of the study.\xa0</p><p>1.26.<span style=""font-size: 7pt;"">\xa0\xa0\xa0</span>The Committees considered that the evidence for nusinersen in the groups under consideration is limited to a small number of studies, but that further high quality evidence is unlikely due to the funding of SMA treatments internationally. </p><p><br></p><h4><span style=""font-family: Arial, sans-serif; font-size: 11pt;"">Risdiplam</span></h4><p>1.27.<span style=""font-size: 7pt;"">\xa0\xa0\xa0</span>The<em> </em>Committees noted that there are currently no published studies evaluating the efficacy and safety of risdiplam specifically in an adult population. However, the SUNFISH trial included individuals with SMA types II and III who were aged 2-25 years (median age 9) old at the time of randomisation (<a href=""https://pubmed.ncbi.nlm.nih.gov/34942136/"" target=""_blank"">Mercuri et al. Lancet neurol. 2022;21:42-52</a>). The Committees noted that 180 participants were included in the study, 22 of whom were aged 18-25 years at randomisation. The Committees noted that 67% of the study population had scoliosis and 25% had had spinal surgery; thus the Committees considered this group to have severely impacted motor function. The Committees noted that results were not stratified into type IIIa, b, or c.</p><p>1.28.<span style=""font-size: 7pt;"">\xa0\xa0\xa0</span>The Committees noted that in the 18–25-year age group, there was no significant improvement in motor function measure: -0.65 (-4.03 to 2.74), however a significant improvement in the revised upper limb module was observed: 1.74 (-1.06 to 4.53). </p><p>1.29.<span style=""font-size: 7pt;"">\xa0\xa0\xa0</span>Members considered that the improvements seen for this group represented clinically meaningful outcomes. </p><p>1.30.<span style=""font-size: 7pt;"">\xa0\xa0\xa0</span>Members considered that while the SUNFISH trial did not include stratified results for type IIIb and IIIc individuals, SMA is a spectrum of disease and so it is reasonable to extrapolate that these group would also receive benefit from treatment.</p><p>1.31.<span style=""font-size: 7pt;"">\xa0\xa0\xa0</span>The Committees considered an article describing the Clinical experience through Early Access Medicines Scheme (EAMs) Northern Ireland for risdiplam for the treatment of adults with SMA (<a href=""https://pubmed.ncbi.nlm.nih.gov/36382958/"" target=""_blank"">McCluskey et al. 2023;67(2):157-71</a>). The study included six participants with a mean age of 33.7 years, none of whom had received prior treatment with onasemnogene (due to age) or nusinersen (due to complex spinal anatomy). There was no change in RULM score or respiratory function. There was an Egan Kallifikation 2 (EK2) Mean change -4.5(95%CI -7.3- -1.7, p=0.009), and a quality-of-life measure (QOLM) Mean change of +10.7(95%CI 1.4-19.5, p=0.027). Patients reported a range of observed benefits including multiple motor improvements. All participants reported an overall improvement in strength, sense of wellbeing, and speech quality.</p><p><br></p><h4><span style=""font-family: Arial, sans-serif; font-size: 11pt;"">General</span></h4><p>1.32.<span style=""font-size: 7pt;"">\xa0\xa0\xa0</span>The Committees considered that where evidence was available for only one treatment (ie. risdiplam or nusinersen) within a patient group, that it was reasonable to assume that both treatments would provide the same or similar level of benefit within that group. The Committees noted that this was due to similar mechanisms of action, biological plausibility, and similar outcomes when studies in other subgroups. </p><p>1.33.<span style=""font-size: 7pt;"">\xa0\xa0\xa0</span>The Committees noted that after the age of 20 years, most of an individual with SMA’s motor neurons may be lost, and thus treatment with nusinersen or risdiplam would not be expected to regain lost function. By contrast, those treated early a greater proportion of motor neurons would be protected, with a resultant greater benefit. Members noted that there was limited available evidence to confirm that loss function cannot be regained with treatment. The Committees considered that for adults with SMA, while the published evidence suggests that treatment would not result in a significant improvement in motor function and other symptoms; the demonstrated maintenance of motor function provides a clinically meaningful outcome, which should not be underestimated.</p><p>1.34.<span style=""font-size: 7pt;"">\xa0\xa0\xa0</span>The Committees noted there was no published evidence which supported the use of nusinersen or risdiplam in individuals with adult-onset SMA (Type IV). </p><p>1.35.<span style=""font-size: 7pt;"">\xa0\xa0\xa0</span>Members considered that is the funding criteria relating to SMN2 copies were widened to allow for individuals to access treatment with up to 3 SMN2 copies, then most people who would later develop SMA symptoms would be diagnosed and treated symptomatically, however. Members considered that extension of the criteria to include 4 SMN2 copies may include individuals with milder phenotypes who have a reduced cost-benefit for treatment. Members commented it would be appropriate to have guidelines in place to ensure those who are identified as having 4 copies SMN2 copies through pre-symptomatic screening are monitored more closely for the development of symptoms.</p><h3><em>Suitability</em></h3><p>1.36.<span style=""font-size: 7pt;"">\xa0\xa0\xa0</span>The Committees noted that nusinersen is administered intrathecally by a health care professional. The Committees considered that administration of nusinersen is often complicated in individuals with severe scoliosis. Members considered that adults with SMA types II and III, particularly those who are non-ambulant may experience significant scoliosis and mobility problems, as well as previous orthopaedic surgery, and therefore those affected may require alternative interventions to administer the treatment (<a href=""https://pubmed.ncbi.nlm.nih.gov/35218574/"" target=""_blank"">Rad et al. Muscle Nerve. 2022;65(5):498-507</a><u>)</u>. The Committees considered that transport to a clinical setting for tri-annual infusions may be difficult for some due to the individuals’ ambulation status and potential distance from treatment centres and socioeconomic status. As such, the Committees considered risdiplam, as an oral treatment, would likely be a more suitable treatment and result in less inequity for non-ambulant adults with SMA.</p><p>1.37.<span style=""font-size: 7pt;"">\xa0\xa0\xa0</span>The Committee considered that due to the size of the risdiplam bottles, the oral liquid would not last long for adult patients. The Committee noted that a tablet form is currently being developed to overcome this problem.</p><h3><em>Cost and saving</em></h3><p>1.38.<span style=""font-size: 7pt;"">\xa0\xa0\xa0</span>The Committees noted that the administration costs associated with giving nusinersen by lumbar puncture were high in comparison with zero administration costs associated with the orally administered risdiplam.</p><p>1.39.<span style=""font-size: 7pt;"">\xa0\xa0\xa0</span>The Committees also considered that the benefit that could be obtained in people who were over 18 years of age at the time of treatment initiation was likely lower than that obtained for people starting treatment at the time of symptom onset (and far lower than that for people diagnosed and treated pre-symptomatically). However, the Committees considered the magnitude of treatment benefit highly uncertain in economic terms, and that while people with treatment may experience a less severe disease phenotype, advice from specialists treating people in this group would need to be obtained to ascertain the magnitude of benefit and a means of expressing and quantifying it in economic modelling.</p><h3><em>Summary for assessment</em></h3><p>1.40.<span style=""font-size: 7pt;"">\xa0\xa0\xa0</span>The <span style=""color: black;"">Advisory Committees considered that the below table summarises its interpretation of the most appropriate PICO (population, intervention, comparator, outcomes) information for nusinersen and risdiplam if they were to be funded in New Zealand for SMA in people who did not meet existing funding criteria. This PICO captures key clinical aspects of the proposal and may be used to frame any future economic assessment by Pharmac staff. This PICO is based on the Advisory Committees’ assessment at this time and may differ from that requested by the applicant. The PICO may change based on new information, additional clinical advice, or further analysis by Pharmac staff.</span></p><p><span style=""color: black;""><span class=""ql-cursor"">\ufeff</span></span><img src=""/apptracker/servlet/rtaImage?eid=a0POZ000009Dz0w&amp;feoid=00N2P000000YsIc&amp;refid=0EMOZ0000005tez"" alt=""image.png""></img></p>', 'fs': '<h3><em>Patient lived experience</em></h3><p>1.1.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0</span>A New Zealander with SMA who had recently moved to Australia to access funded treatment and a clinician treating SMA with nusinersen and risdiplam in Australia shared their experiences with the Rare Disorders Advisory Committee, Neurological Committee observers and Pharmac staff. The Committees and Pharmac staff valued this opportunity and considered that it helped to frame the Committees’ discussions about treatment of SMA in adults with a different perspective.</p><p>1.2.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0</span>The person with SMA described the losses experienced due to SMA as a cumulative trauma that is constantly affecting their life. They recounted the difficult decision to move from New Zealand in order to access funded treatment, and how their family had to sacrifice being near their support network for this purpose. </p><p>1.3.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0</span>The person described how commencing treatment with nusinersen as an adult had positively impacted their life. They recounted that since receiving treatment they were able to stand stronger, walk further and complete tasks that they had previously lost the ability to do due to SMA symptoms. They described how treatment offered a better life for them, their family, and the economy as they had increased ability to work.\xa0</p><p>1.4.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0</span>The clinician treating SMA in adults described how they had observed stabilisation or improvements of SMA symptoms in almost all people they had treated with nusinersen or risdiplam. They recounted that the people they treated shared treatment expectations of stabilisation and maintaining independence, with anything more being experienced as a bonus. </p><p>1.5.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0</span>Both the individual with SMA, and the clinician emphasised that the benefits of treatment with nusinersen or risdiplam should not be underestimated, as even small benefits could make significant differences to people&#39;s lives. </p><h3><em>Māori impact</em></h3><p>1.6.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committees discussed the impact of funding nusinersen and risdiplam for SMA groups currently under consideration on Māori health areas of focus and Māori health outcomes. The Committees noted unpublished 2023 reporting by Richard Roxburgh and colleagues of the prevalence of SMA in Māori people being approximately 0.34/100,000 live births and corresponding incidence 1.7/100,000 live births (95% CI 0 to 9.3).</p><p>1.7.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committees noted that SMA is not included as a Māori health area of focus in Te Pātaka Whaioranga - Pharmac’s Māori responsiveness strategy.</p><h3><em>Background</em></h3><p>1.8.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committees noted that from 1 January 2023, nusinersen has been funded for people aged 18 years and under with pre-symptomatic SMA or symptomatic SMA types I, II or IIIa. The Committees noted that Pharmac has recently consulted on a proposal to fund risdiplam from 1 May 2023 with the same access criteria as nusinersen.</p><p>1.9.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committees noted that substantive feedback was received in response to Pharmac’s consultation to fund nusinersen and risdiplam, regarding access criteria. The Committees noted that consultation responses included feedback that treatments should be funded for all people with SMA, including those who start treatment after 18 years of age with the types otherwise eligible within the currently proposed criteria, and for individuals with SMA types IIIb, IIIc and IV.</p><p>1.10.<span style=""font-size: 7pt;"">\xa0\xa0\xa0</span>The current eligibility criteria reflect the population requested in the funding application, the people identified by our clinical advisors as having the highest unmet health need and the most potential to benefit from treatment and aligns with the clinical trial evidence that was considered by our clinical advisors at the time. More information can be found in the Application Tracker record for nusinersen (for <a href=""https://connect.pharmac.govt.nz/apptracker/s/application-public/a102P000008puSr/p001050"" target=""_blank"">SMA types I II and III</a> and <a href=""https://connect.pharmac.govt.nz/apptracker/s/application-public/a102P000009QXCv/p001488"" target=""_blank"">pre-symptomatic SMA</a>).</p><h3><em>Health Need</em></h3><p>1.11.<span style=""font-size: 7pt;"">\xa0\xa0\xa0</span>The Committees noted that the incidence of SMA in New Zealand is approximately 0.8/10,000 live births, equating to approximately 4-5 incident cases of SMA per year as per an unpublished study by Rodrigues et al (2021). The Committees noted that the unpublished publication described the current prevalence of SMA in New Zealand as 1.7/100,000 people, or approximately 80 people in total.</p><p>1.12.<span style=""font-size: 7pt;"">\xa0\xa0\xa0</span>The Committees noted that the unpublished article by Rodrigues et al which stated that epidemiological studies suggest that 50-60% of incident SMA cases are SMA type 1, however due to the short life expectancy SMA type 1 is less prevalent than other forms.\xa0</p><p>1.13.<span style=""font-size: 7pt;"">\xa0\xa0\xa0</span>The Committees noted that SMA presents as a spectrum disease, and that there can be overlap in symptom severity between types. Members noted that the types of SMA are largely defined by the time of symptom onset, but also that there is an inverse correlation between severity and SMN2 copy number. The Committees noted that treatment in the pre-symptomatic setting is based on SMN2 copy number, as symptoms have not yet developed. </p><p>1.14.<span style=""font-size: 7pt;"">\xa0\xa0\xa0</span>The Committees noted data from the New Zealand SMA registry reporting that around 40 individuals on the registry were over 18 years of age as of 1 March 2023. The Committees noted that due to the voluntary nature of the registry, all people may not be included.</p><p>1.15.<span style=""font-size: 7pt;"">\xa0\xa0\xa0</span>The Committees noted that individuals who are pre-symptomatic are unable to be classified as type I, II, III or IV, which are defined based on time of symptom onset; and so are classified by the number of SMN2 copies, due to current evidence indicating that number of SMN2 copies correlating inversely with disease severity.</p><p><br></p><h4><span style=""font-family: Arial, sans-serif; font-size: 11pt;"">Type IIIb, III c and undefined III:</span></h4><p>1.16.<span style=""font-size: 7pt;"">\xa0\xa0\xa0</span>The Committees noted that individuals with SMA type III typically develop the ability to walk without assistance and have an unaffected life expectancy, however the Committees recognised that there are a range of mobility limitations ranging from abnormal gait caused by weakness in their hip and/or thigh muscles to loss of ambulation during adolescence or adulthood. In some patients, there may be considerable burden of disease with reduced employment, higher health needs, and psychological impacts that may be present for much of the individual’s adult life. The Committees considered that the impact of SMA over time for people with SMA type IIIb should not be underestimated, noting that they may lose ambulation and require a wheelchair later in life.</p><p>1.17.<span style=""font-size: 7pt;"">\xa0\xa0\xa0</span>The Committees considered that all individuals with SMA type III represent a high proportion of the prevalent population (given lower to low survival rates in types I and II). The Committees considered that individuals with type IIIa were less likely to be walking at 10 years of age than those with SMA type IIIb. The Committees considered that individuals with type IIIa may have similar orthopaedic surgery needs to individuals with SMA type II, whereas individuals with type IIIb usually reach normal early developmental milestones.</p><p>1.18.<span style=""font-size: 7pt;"">\xa0\xa0\xa0</span>The Committees considered that people aged 18 years and under with type IIIb, IIIc and undefined III had a high unmet health need. Members considered that at it can be difficult to differentiate between subtypes IIIa, b and c from due to phenotypic overlap and that this in part is likely explained by commonalities in SMN2 copy numbers.</p><p> </p><h4><span style=""font-family: Arial, sans-serif; font-size: 11pt;"">Adults with type II and III:</span></h4><p>1.19.<span style=""font-size: 7pt;"">\xa0\xa0\xa0</span>The Committees considered that people aged 19 years and over with SMA Type II and III SMA have high unmet health need. Members noted that adults with SMA, as with children with SMA, can experience substantial morbidity and in some cases early mortality. Members noted the impact of frequent medical appointments, hospital admissions, and reliance on carers. The Committees considered that SMA is a progressive disease, with symptoms gradually worsening over time, including the loss of ambulation.</p><p>1.20.<span style=""font-size: 7pt;"">\xa0\xa0\xa0</span>The Committees considered the health need of families and whānau of people with SMA is similarly high across subtypes and age. The Committees reiterated the comments from PTAC in August 2018; that there is a high health need for family, whānau, and caregivers of SMA patients, and that some families have left New Zealand to seek treatment internationally, such as moving to Australia to access funded treatment, in some cases leaving behind their families, whānau and support systems. The Committees considered that only those individuals belonging to households with the financial means to relocate can make the choice to move overseas, and that those living in more difficult socioeconomic circumstances would not have this option. \xa0</p><p><br></p><h4><span style=""font-family: Arial, sans-serif; font-size: 11pt;"">Type IV</span></h4><p>1.21.<span style=""font-size: 7pt;"">\xa0\xa0\xa0</span>The Committees considered that people with SMA type IV have a low health need compared with those with other SMA types. The Committees considered that the nature of SMA type IV symptoms is poorly defined. The Committees noted reports of individuals in their 20s to 40s being ambulant and requiring no respiratory support and/or maintaining a sedentary occupation (<a href=""https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4628728/"" target=""_blank"">Kolb et al. Neurol Clin 2015; 33:831</a>). The Committees considered that SMA type IV is a slow progressing form of SMA where limb weakness occurs gradually, and often without major motor impairments, respiratory impacts or changes to mortality. The Committees noted that the average age at symptom onset of SMA type IV is also poorly defined and that the subtype is broadly defined by individuals experiencing the onset of symptoms after the age of 18 years. The Committees noted that individuals with SMA type IV have a standard life expectancy.</p><p><br></p><h3><em>Health Benefit</em></h3><h4><span style=""font-family: Arial, sans-serif; font-size: 11pt;"">Nusinersen</span></h4><p>1.22.<span style=""font-size: 7pt;"">\xa0\xa0\xa0</span>The Committees noted results from an observational prospective longitudinal follow-up study which aimed to determine changes in motor and respiratory function after treatment with nusinersen in adults with SMA (<a href=""https://cp.neurology.org/content/11/3/e317"" target=""_blank"">Duong et al. Neurol Clin Pract. 2021;11(3):e317-e327</a>). The Committees considered that the study’s population most closely matched the population of individuals with SMA in New Zealand in regard to ambulation status. The Committees noted that individuals were treated for a mean treatment duration of 12.5 months. The Committees considered that some broad objective measures, including various motor and respiratory measures, reported stability rather than the expected decline, while some results reported a non-significant trend towards improvement. The Committees noted that outcomes were not analysed according to subtype of SMA. The Committees considered limitations of the study included that it was observational, non-randomised and, not blinded (but considered that blinded studies were now unlikely to be conducted), the short follow up period, possible selection bias, and imprecision with wide confidence intervals.\xa0</p><p>1.23.<span style=""font-size: 7pt;"">\xa0\xa0\xa0</span>The Committees noted a prospective three year SMArtCARE Registry-based observational longitudinal follow-up study that assessed improvements in walking distance during nusinersen treatment (<a href=""https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9881023/"" target=""_blank"">Pechmann et al. 2023;10(1):29-40</a>). The Committees noted that the study included adult as well as paediatric participants, all whom were walking independently at the start of the study. The Committees noted the mean age of SMA symptom onset was 11 years, and mean age at the start of treatment was 37 years. The Committees noted that 26% of adult participants experienced clinically meaningful improvement of equal to or more than 30 metres in the 6-minute walk time (6MWT) test at the last available visit (up to 38 months).</p><p>1.24.<span style=""font-size: 7pt;"">\xa0\xa0\xa0</span>The Committees also noted the following reviews:</p><p class=""ql-indent-1""><span style=""font-family: Symbol;"">·</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span><a href=""https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8515709/"" target=""_blank"">Coratti et </a><a href=""https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8515709/"" target=""_blank"" style=""color: windowtext;"">al</a><a href=""https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8515709/"" target=""_blank"">. Orphanet J Rare Dis. 2021;16(1):430</a></p><p class=""ql-indent-1""><span style=""font-family: Symbol;"">·</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span><a href=""https://pubmed.ncbi.nlm.nih.gov/35178673/"" target=""_blank"">Gavriilaki et al. Neurotherapeutics. 2022;19(2):464-75</a></p><p class=""ql-indent-1""><span style=""color: windowtext; font-family: Symbol;"">·</span><span style=""color: windowtext; font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span><a href=""https://pubmed.ncbi.nlm.nih.gov/35218574/"" target=""_blank"">Rad et al. Muscle Nerve. 2022;65(5):498-507</a></p><p class=""ql-indent-1""><span style=""font-family: Symbol;"">·</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span><a href=""https://www.ncbi.nlm.nih.gov/books/NBK566621/"" target=""_blank"">Janoudi et ak. Ottawa (ON): Canadian Agency for Drugs and Technologies in Health. 2020.</a></p><p>1.25<em>.</em><span style=""font-size: 7pt;"">\xa0\xa0\xa0</span>Committee noted results from <a href=""https://pubmed.ncbi.nlm.nih.gov/31019106/"" target=""_blank"">Darras et al. Neurology. 2019;92(21):e2492-e2506</a>, a phase 1b/2a study which followed 28 children with SMA, 18 of whom had type III disease. All motor outcomes improved over the 715 day extension arm of the study.\xa0</p><p>1.26.<span style=""font-size: 7pt;"">\xa0\xa0\xa0</span>The Committees considered that the evidence for nusinersen in the groups under consideration is limited to a small number of studies, but that further high quality evidence is unlikely due to the funding of SMA treatments internationally. </p><p><br></p><h4><span style=""font-family: Arial, sans-serif; font-size: 11pt;"">Risdiplam</span></h4><p>1.27.<span style=""font-size: 7pt;"">\xa0\xa0\xa0</span>The<em> </em>Committees noted that there are currently no published studies evaluating the efficacy and safety of risdiplam specifically in an adult population. However, the SUNFISH trial included individuals with SMA types II and III who were aged 2-25 years (median age 9) old at the time of randomisation (<a href=""https://pubmed.ncbi.nlm.nih.gov/34942136/"" target=""_blank"">Mercuri et al. Lancet neurol. 2022;21:42-52</a>). The Committees noted that 180 participants were included in the study, 22 of whom were aged 18-25 years at randomisation. The Committees noted that 67% of the study population had scoliosis and 25% had had spinal surgery; thus the Committees considered this group to have severely impacted motor function. The Committees noted that results were not stratified into type IIIa, b, or c.</p><p>1.28.<span style=""font-size: 7pt;"">\xa0\xa0\xa0</span>The Committees noted that in the 18–25-year age group, there was no significant improvement in motor function measure: -0.65 (-4.03 to 2.74), however a significant improvement in the revised upper limb module was observed: 1.74 (-1.06 to 4.53). </p><p>1.29.<span style=""font-size: 7pt;"">\xa0\xa0\xa0</span>Members considered that the improvements seen for this group represented clinically meaningful outcomes. </p><p>1.30.<span style=""font-size: 7pt;"">\xa0\xa0\xa0</span>Members considered that while the SUNFISH trial did not include stratified results for type IIIb and IIIc individuals, SMA is a spectrum of disease and so it is reasonable to extrapolate that these group would also receive benefit from treatment.</p><p>1.31.<span style=""font-size: 7pt;"">\xa0\xa0\xa0</span>The Committees considered an article describing the Clinical experience through Early Access Medicines Scheme (EAMs) Northern Ireland for risdiplam for the treatment of adults with SMA (<a href=""https://pubmed.ncbi.nlm.nih.gov/36382958/"" target=""_blank"">McCluskey et al. 2023;67(2):157-71</a>). The study included six participants with a mean age of 33.7 years, none of whom had received prior treatment with onasemnogene (due to age) or nusinersen (due to complex spinal anatomy). There was no change in RULM score or respiratory function. There was an Egan Kallifikation 2 (EK2) Mean change -4.5(95%CI -7.3- -1.7, p=0.009), and a quality-of-life measure (QOLM) Mean change of +10.7(95%CI 1.4-19.5, p=0.027). Patients reported a range of observed benefits including multiple motor improvements. All participants reported an overall improvement in strength, sense of wellbeing, and speech quality.</p><p><br></p><h4><span style=""font-family: Arial, sans-serif; font-size: 11pt;"">General</span></h4><p>1.32.<span style=""font-size: 7pt;"">\xa0\xa0\xa0</span>The Committees considered that where evidence was available for only one treatment (ie. risdiplam or nusinersen) within a patient group, that it was reasonable to assume that both treatments would provide the same or similar level of benefit within that group. The Committees noted that this was due to similar mechanisms of action, biological plausibility, and similar outcomes when studies in other subgroups. </p><p>1.33.<span style=""font-size: 7pt;"">\xa0\xa0\xa0</span>The Committees noted that after the age of 20 years, most of an individual with SMA’s motor neurons may be lost, and thus treatment with nusinersen or risdiplam would not be expected to regain lost function. By contrast, those treated early a greater proportion of motor neurons would be protected, with a resultant greater benefit. Members noted that there was limited available evidence to confirm that loss function cannot be regained with treatment. The Committees considered that for adults with SMA, while the published evidence suggests that treatment would not result in a significant improvement in motor function and other symptoms; the demonstrated maintenance of motor function provides a clinically meaningful outcome, which should not be underestimated.</p><p>1.34.<span style=""font-size: 7pt;"">\xa0\xa0\xa0</span>The Committees noted there was no published evidence which supported the use of nusinersen or risdiplam in individuals with adult-onset SMA (Type IV). </p><p>1.35.<span style=""font-size: 7pt;"">\xa0\xa0\xa0</span>Members considered that is the funding criteria relating to SMN2 copies were widened to allow for individuals to access treatment with up to 3 SMN2 copies, then most people who would later develop SMA symptoms would be diagnosed and treated symptomatically, however. Members considered that extension of the criteria to include 4 SMN2 copies may include individuals with milder phenotypes who have a reduced cost-benefit for treatment. Members commented it would be appropriate to have guidelines in place to ensure those who are identified as having 4 copies SMN2 copies through pre-symptomatic screening are monitored more closely for the development of symptoms.</p><h3><em>Suitability</em></h3><p>1.36.<span style=""font-size: 7pt;"">\xa0\xa0\xa0</span>The Committees noted that nusinersen is administered intrathecally by a health care professional. The Committees considered that administration of nusinersen is often complicated in individuals with severe scoliosis. Members considered that adults with SMA types II and III, particularly those who are non-ambulant may experience significant scoliosis and mobility problems, as well as previous orthopaedic surgery, and therefore those affected may require alternative interventions to administer the treatment (<a href=""https://pubmed.ncbi.nlm.nih.gov/35218574/"" target=""_blank"">Rad et al. Muscle Nerve. 2022;65(5):498-507</a><u>)</u>. The Committees considered that transport to a clinical setting for tri-annual infusions may be difficult for some due to the individuals’ ambulation status and potential distance from treatment centres and socioeconomic status. As such, the Committees considered risdiplam, as an oral treatment, would likely be a more suitable treatment and result in less inequity for non-ambulant adults with SMA.</p><p>1.37.<span style=""font-size: 7pt;"">\xa0\xa0\xa0</span>The Committee considered that due to the size of the risdiplam bottles, the oral liquid would not last long for adult patients. The Committee noted that a tablet form is currently being developed to overcome this problem.</p><h3><em>Cost and saving</em></h3><p>1.38.<span style=""font-size: 7pt;"">\xa0\xa0\xa0</span>The Committees noted that the administration costs associated with giving nusinersen by lumbar puncture were high in comparison with zero administration costs associated with the orally administered risdiplam.</p><p>1.39.<span style=""font-size: 7pt;"">\xa0\xa0\xa0</span>The Committees also considered that the benefit that could be obtained in people who were over 18 years of age at the time of treatment initiation was likely lower than that obtained for people starting treatment at the time of symptom onset (and far lower than that for people diagnosed and treated pre-symptomatically). However, the Committees considered the magnitude of treatment benefit highly uncertain in economic terms, and that while people with treatment may experience a less severe disease phenotype, advice from specialists treating people in this group would need to be obtained to ascertain the magnitude of benefit and a means of expressing and quantifying it in economic modelling.</p><h3><em>Summary for assessment</em></h3><p>1.40.<span style=""font-size: 7pt;"">\xa0\xa0\xa0</span>The <span style=""color: black;"">Advisory Committees considered that the below table summarises its interpretation of the most appropriate PICO (population, intervention, comparator, outcomes) information for nusinersen and risdiplam if they were to be funded in New Zealand for SMA in people who did not meet existing funding criteria. This PICO captures key clinical aspects of the proposal and may be used to frame any future economic assessment by Pharmac staff. This PICO is based on the Advisory Committees’ assessment at this time and may differ from that requested by the applicant. The PICO may change based on new information, additional clinical advice, or further analysis by Pharmac staff.</span></p><p><span style=""color: black;""><span class=""ql-cursor"">\ufeff</span></span><img src=""/apptracker/servlet/rtaImage?eid=a0POZ000009Dz0w&amp;feoid=00N2P000000YsIc&amp;refid=0EMOZ0000005tez"" alt=""image.png""></img></p>', 'change': None}, 'Published_Application': {'s': '<p>1.1.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0</span>Following feedback on the consultations for the funding of nusinersen and risdiplam, the Advisory Committees reviewed applications for these SMA treatments for the treatment of spinal muscular atrophy (SMA) in people not funded by the existing funding criteria, namely:</p><p class=""ql-indent-1""><span style=""font-family: Symbol;"">·</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>people with SMA types IIIb, IIIc and undefined III aged 18 years and under (symptomatic after 3 years of age)</p><p class=""ql-indent-1""><span style=""font-family: Symbol;"">·</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>people with SMA type II and III who are aged 19 years and over</p><p class=""ql-indent-1""><span style=""font-family: Symbol;"">·</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>people with SMA type IV (aged 19 years and over at symptom onset).</p><p>1.2.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0</span>The Advisory Committees took into account, where applicable, Pharmac’s relevant decision-making framework when considering this agenda item.</p>', 'fs': '<p>1.1.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0</span>Following feedback on the consultations for the funding of nusinersen and risdiplam, the Advisory Committees reviewed applications for these SMA treatments for the treatment of spinal muscular atrophy (SMA) in people not funded by the existing funding criteria, namely:</p><p class=""ql-indent-1""><span style=""font-family: Symbol;"">·</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>people with SMA types IIIb, IIIc and undefined III aged 18 years and under (symptomatic after 3 years of age)</p><p class=""ql-indent-1""><span style=""font-family: Symbol;"">·</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>people with SMA type II and III who are aged 19 years and over</p><p class=""ql-indent-1""><span style=""font-family: Symbol;"">·</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>people with SMA type IV (aged 19 years and over at symptom onset).</p><p>1.2.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0</span>The Advisory Committees took into account, where applicable, Pharmac’s relevant decision-making framework when considering this agenda item.</p>', 'change': None}, 'PTAC_Comments': {'s': None, 'fs': None, 'change': None}, 'Outcome': {'s': 'High', 'fs': 'High', 'change': None}, 'Links': {'s': None, 'fs': None, 'change': None}, 'Formatted_Date': {'s': 'Aug 2023', 'fs': 'Aug 2023', 'change': None}, 'Event_Description': {'s': 'Clinical advice received from Rare Disorders Advisory Committee at meeting Tuesday 7 March 2023.', 'fs': 'Clinical advice received from Rare Disorders Advisory Committee at meeting Tuesday 7 March 2023.', 'change': None}, 'e': {'attributes': {'type': 'Application_Event__c', 'url': '/services/data/v65.0/sobjects/Application_Event__c/a0POZ000009Dz0w2AC'}, 'Id': 'a0POZ000009Dz0w2AC', 'Event_Date__c': '2023-08-11', 'Event_Description__c': 'Clinical advice received from Rare Disorders Advisory Committee at meeting Tuesday 7 March 2023.', 'Stage__c': 'Seeking Clinical Advice', 'Outcome__c': 'High', 'Formatted_Date__c': 'Aug 2023', 'Published_Recommendation__c': '<p>1.1.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0</span>The Advisory Committees <strong>recommended</strong> that the funded access to nusinersen and/or risdiplam be widened to include SMA types IIIb, IIIc and undefined type III within the context of treatments for rare disorders and for neurological disorders with a <strong>high priority</strong> subject to the following Special Authority criteria (changes marked from current funded criteria):</p><p><br></p><p class=""ql-indent-1""><span style=""font-size: 9pt;"">Initial application from any relevant practitioner. Approvals valid for 12 months for applications meeting the following:</span></p><p class=""ql-indent-1""><span style=""font-size: 9pt;"">All of the following:</span></p><p class=""ql-indent-2""><span style=""font-size: 9pt;"">1</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0</span><span style=""font-size: 9pt;"">Person has genetic documentation of a homozygous </span><em style=""font-size: 9pt;"">SMN1</em><span style=""font-size: 9pt;""> gene deletion, homozygous </span><em style=""font-size: 9pt;"">SMN1</em><span style=""font-size: 9pt;""> point mutation, or compound heterozygous mutation; and</span></p><p class=""ql-indent-2""><span style=""font-size: 9pt;"">2</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0</span><span style=""font-size: 9pt;"">Person is 18 years of age or under; and</span></p><p class=""ql-indent-2""><span style=""font-size: 9pt;"">3</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0</span><span style=""font-size: 9pt;"">Either</span></p><p class=""ql-indent-3""><span style=""font-size: 9pt;"">3.1</span><span style=""font-size: 7pt;"">\xa0\xa0</span><span style=""font-size: 9pt;"">Person has experienced the defined signs and symptoms of SMA type I, II or III</span><strike style=""font-size: 9pt;"">a prior to three years of age</strike><span style=""font-size: 9pt;"">; or</span></p><p class=""ql-indent-3""><span style=""font-size: 9pt;"">3.2</span><span style=""font-size: 7pt;"">\xa0\xa0</span><span style=""font-size: 9pt;"">Both:</span></p><p class=""ql-indent-4""><span style=""font-size: 9pt;"">3.2.1</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0</span><span style=""font-size: 9pt;"">Person is pre-symptomatic; and</span></p><p class=""ql-indent-4""><span style=""font-size: 12px;"">3.2.2\xa0\xa0\xa0\xa0\xa0</span><span style=""font-size: 9pt;"">Person has three or less copies of SMN2.</span></p><p class=""ql-indent-1""><span style=""font-size: 9pt;"">\xa0</span></p><p class=""ql-indent-1""><span style=""font-size: 9pt;"">Renewal from any relevant practitioner. Renewals valid for 12 months. All of the following:</span></p><p class=""ql-indent-2""><span style=""font-size: 9pt;"">1</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0</span><span style=""font-size: 9pt;"">There has been demonstrated maintenance of motor milestone function since treatment initiation; and</span></p><p class=""ql-indent-2""><span style=""font-size: 9pt;"">2</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0</span><span style=""font-size: 9pt;"">Person does not require invasive permanent ventilation (at least 16 hours per day), in the absence of a potentially reversible cause while being treated with nusinersen; and</span></p><p class=""ql-indent-2""><span style=""font-size: 9pt;"">3</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0</span><strike style=""font-size: 9pt;"">Nusinersen </strike><strong style=""font-size: 9pt;"">N</strong><strike style=""font-size: 9pt;"">n</strike><span style=""font-size: 9pt;"">ot to be administered in combination with other SMA disease modifying treatments or gene therapy.</span></p><p class=""ql-indent-1""><span style=""font-size: 9pt;"">\xa0</span></p><p>1.2.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0</span>In making this recommendation the Committees considered:</p><p class=""ql-indent-1""><span style=""font-family: Symbol;"">·</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The high unmet health need of people with SMA type III;</p><p class=""ql-indent-1""><span style=""font-family: Symbol;"">·</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The overlap in health need between people with SMA type IIIa and types IIIb and IIIc;</p><p class=""ql-indent-1""><span style=""font-family: Symbol;"">·</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>While the SUNFISH trial did not include stratified results for type IIIb and IIIc individuals, there was sufficient evidence to show that there was treatment benefit for adults with SMA types II and III in the form of maintaining physical function</p>', 'Published_Application__c': '<p>1.1.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0</span>Following feedback on the consultations for the funding of nusinersen and risdiplam, the Advisory Committees reviewed applications for these SMA treatments for the treatment of spinal muscular atrophy (SMA) in people not funded by the existing funding criteria, namely:</p><p class=""ql-indent-1""><span style=""font-family: Symbol;"">·</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>people with SMA types IIIb, IIIc and undefined III aged 18 years and under (symptomatic after 3 years of age)</p><p class=""ql-indent-1""><span style=""font-family: Symbol;"">·</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>people with SMA type II and III who are aged 19 years and over</p><p class=""ql-indent-1""><span style=""font-family: Symbol;"">·</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>people with SMA type IV (aged 19 years and over at symptom onset).</p><p>1.2.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0</span>The Advisory Committees took into account, where applicable, Pharmac’s relevant decision-making framework when considering this agenda item.</p>', 'Published_Discussion__c': '<h3><em>Patient lived experience</em></h3><p>1.1.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0</span>A New Zealander with SMA who had recently moved to Australia to access funded treatment and a clinician treating SMA with nusinersen and risdiplam in Australia shared their experiences with the Rare Disorders Advisory Committee, Neurological Committee observers and Pharmac staff. The Committees and Pharmac staff valued this opportunity and considered that it helped to frame the Committees’ discussions about treatment of SMA in adults with a different perspective.</p><p>1.2.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0</span>The person with SMA described the losses experienced due to SMA as a cumulative trauma that is constantly affecting their life. They recounted the difficult decision to move from New Zealand in order to access funded treatment, and how their family had to sacrifice being near their support network for this purpose. </p><p>1.3.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0</span>The person described how commencing treatment with nusinersen as an adult had positively impacted their life. They recounted that since receiving treatment they were able to stand stronger, walk further and complete tasks that they had previously lost the ability to do due to SMA symptoms. They described how treatment offered a better life for them, their family, and the economy as they had increased ability to work.\xa0</p><p>1.4.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0</span>The clinician treating SMA in adults described how they had observed stabilisation or improvements of SMA symptoms in almost all people they had treated with nusinersen or risdiplam. They recounted that the people they treated shared treatment expectations of stabilisation and maintaining independence, with anything more being experienced as a bonus. </p><p>1.5.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0</span>Both the individual with SMA, and the clinician emphasised that the benefits of treatment with nusinersen or risdiplam should not be underestimated, as even small benefits could make significant differences to people&#39;s lives. </p><h3><em>Māori impact</em></h3><p>1.6.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committees discussed the impact of funding nusinersen and risdiplam for SMA groups currently under consideration on Māori health areas of focus and Māori health outcomes. The Committees noted unpublished 2023 reporting by Richard Roxburgh and colleagues of the prevalence of SMA in Māori people being approximately 0.34/100,000 live births and corresponding incidence 1.7/100,000 live births (95% CI 0 to 9.3).</p><p>1.7.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committees noted that SMA is not included as a Māori health area of focus in Te Pātaka Whaioranga - Pharmac’s Māori responsiveness strategy.</p><h3><em>Background</em></h3><p>1.8.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committees noted that from 1 January 2023, nusinersen has been funded for people aged 18 years and under with pre-symptomatic SMA or symptomatic SMA types I, II or IIIa. The Committees noted that Pharmac has recently consulted on a proposal to fund risdiplam from 1 May 2023 with the same access criteria as nusinersen.</p><p>1.9.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committees noted that substantive feedback was received in response to Pharmac’s consultation to fund nusinersen and risdiplam, regarding access criteria. The Committees noted that consultation responses included feedback that treatments should be funded for all people with SMA, including those who start treatment after 18 years of age with the types otherwise eligible within the currently proposed criteria, and for individuals with SMA types IIIb, IIIc and IV.</p><p>1.10.<span style=""font-size: 7pt;"">\xa0\xa0\xa0</span>The current eligibility criteria reflect the population requested in the funding application, the people identified by our clinical advisors as having the highest unmet health need and the most potential to benefit from treatment and aligns with the clinical trial evidence that was considered by our clinical advisors at the time. More information can be found in the Application Tracker record for nusinersen (for <a href=""https://connect.pharmac.govt.nz/apptracker/s/application-public/a102P000008puSr/p001050"" target=""_blank"">SMA types I II and III</a> and <a href=""https://connect.pharmac.govt.nz/apptracker/s/application-public/a102P000009QXCv/p001488"" target=""_blank"">pre-symptomatic SMA</a>).</p><h3><em>Health Need</em></h3><p>1.11.<span style=""font-size: 7pt;"">\xa0\xa0\xa0</span>The Committees noted that the incidence of SMA in New Zealand is approximately 0.8/10,000 live births, equating to approximately 4-5 incident cases of SMA per year as per an unpublished study by Rodrigues et al (2021). The Committees noted that the unpublished publication described the current prevalence of SMA in New Zealand as 1.7/100,000 people, or approximately 80 people in total.</p><p>1.12.<span style=""font-size: 7pt;"">\xa0\xa0\xa0</span>The Committees noted that the unpublished article by Rodrigues et al which stated that epidemiological studies suggest that 50-60% of incident SMA cases are SMA type 1, however due to the short life expectancy SMA type 1 is less prevalent than other forms.\xa0</p><p>1.13.<span style=""font-size: 7pt;"">\xa0\xa0\xa0</span>The Committees noted that SMA presents as a spectrum disease, and that there can be overlap in symptom severity between types. Members noted that the types of SMA are largely defined by the time of symptom onset, but also that there is an inverse correlation between severity and SMN2 copy number. The Committees noted that treatment in the pre-symptomatic setting is based on SMN2 copy number, as symptoms have not yet developed. </p><p>1.14.<span style=""font-size: 7pt;"">\xa0\xa0\xa0</span>The Committees noted data from the New Zealand SMA registry reporting that around 40 individuals on the registry were over 18 years of age as of 1 March 2023. The Committees noted that due to the voluntary nature of the registry, all people may not be included.</p><p>1.15.<span style=""font-size: 7pt;"">\xa0\xa0\xa0</span>The Committees noted that individuals who are pre-symptomatic are unable to be classified as type I, II, III or IV, which are defined based on time of symptom onset; and so are classified by the number of SMN2 copies, due to current evidence indicating that number of SMN2 copies correlating inversely with disease severity.</p><p><br></p><h4><span style=""font-family: Arial, sans-serif; font-size: 11pt;"">Type IIIb, III c and undefined III:</span></h4><p>1.16.<span style=""font-size: 7pt;"">\xa0\xa0\xa0</span>The Committees noted that individuals with SMA type III typically develop the ability to walk without assistance and have an unaffected life expectancy, however the Committees recognised that there are a range of mobility limitations ranging from abnormal gait caused by weakness in their hip and/or thigh muscles to loss of ambulation during adolescence or adulthood. In some patients, there may be considerable burden of disease with reduced employment, higher health needs, and psychological impacts that may be present for much of the individual’s adult life. The Committees considered that the impact of SMA over time for people with SMA type IIIb should not be underestimated, noting that they may lose ambulation and require a wheelchair later in life.</p><p>1.17.<span style=""font-size: 7pt;"">\xa0\xa0\xa0</span>The Committees considered that all individuals with SMA type III represent a high proportion of the prevalent population (given lower to low survival rates in types I and II). The Committees considered that individuals with type IIIa were less likely to be walking at 10 years of age than those with SMA type IIIb. The Committees considered that individuals with type IIIa may have similar orthopaedic surgery needs to individuals with SMA type II, whereas individuals with type IIIb usually reach normal early developmental milestones.</p><p>1.18.<span style=""font-size: 7pt;"">\xa0\xa0\xa0</span>The Committees considered that people aged 18 years and under with type IIIb, IIIc and undefined III had a high unmet health need. Members considered that at it can be difficult to differentiate between subtypes IIIa, b and c from due to phenotypic overlap and that this in part is likely explained by commonalities in SMN2 copy numbers.</p><p> </p><h4><span style=""font-family: Arial, sans-serif; font-size: 11pt;"">Adults with type II and III:</span></h4><p>1.19.<span style=""font-size: 7pt;"">\xa0\xa0\xa0</span>The Committees considered that people aged 19 years and over with SMA Type II and III SMA have high unmet health need. Members noted that adults with SMA, as with children with SMA, can experience substantial morbidity and in some cases early mortality. Members noted the impact of frequent medical appointments, hospital admissions, and reliance on carers. The Committees considered that SMA is a progressive disease, with symptoms gradually worsening over time, including the loss of ambulation.</p><p>1.20.<span style=""font-size: 7pt;"">\xa0\xa0\xa0</span>The Committees considered the health need of families and whānau of people with SMA is similarly high across subtypes and age. The Committees reiterated the comments from PTAC in August 2018; that there is a high health need for family, whānau, and caregivers of SMA patients, and that some families have left New Zealand to seek treatment internationally, such as moving to Australia to access funded treatment, in some cases leaving behind their families, whānau and support systems. The Committees considered that only those individuals belonging to households with the financial means to relocate can make the choice to move overseas, and that those living in more difficult socioeconomic circumstances would not have this option. \xa0</p><p><br></p><h4><span style=""font-family: Arial, sans-serif; font-size: 11pt;"">Type IV</span></h4><p>1.21.<span style=""font-size: 7pt;"">\xa0\xa0\xa0</span>The Committees considered that people with SMA type IV have a low health need compared with those with other SMA types. The Committees considered that the nature of SMA type IV symptoms is poorly defined. The Committees noted reports of individuals in their 20s to 40s being ambulant and requiring no respiratory support and/or maintaining a sedentary occupation (<a href=""https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4628728/"" target=""_blank"">Kolb et al. Neurol Clin 2015; 33:831</a>). The Committees considered that SMA type IV is a slow progressing form of SMA where limb weakness occurs gradually, and often without major motor impairments, respiratory impacts or changes to mortality. The Committees noted that the average age at symptom onset of SMA type IV is also poorly defined and that the subtype is broadly defined by individuals experiencing the onset of symptoms after the age of 18 years. The Committees noted that individuals with SMA type IV have a standard life expectancy.</p><p><br></p><h3><em>Health Benefit</em></h3><h4><span style=""font-family: Arial, sans-serif; font-size: 11pt;"">Nusinersen</span></h4><p>1.22.<span style=""font-size: 7pt;"">\xa0\xa0\xa0</span>The Committees noted results from an observational prospective longitudinal follow-up study which aimed to determine changes in motor and respiratory function after treatment with nusinersen in adults with SMA (<a href=""https://cp.neurology.org/content/11/3/e317"" target=""_blank"">Duong et al. Neurol Clin Pract. 2021;11(3):e317-e327</a>). The Committees considered that the study’s population most closely matched the population of individuals with SMA in New Zealand in regard to ambulation status. The Committees noted that individuals were treated for a mean treatment duration of 12.5 months. The Committees considered that some broad objective measures, including various motor and respiratory measures, reported stability rather than the expected decline, while some results reported a non-significant trend towards improvement. The Committees noted that outcomes were not analysed according to subtype of SMA. The Committees considered limitations of the study included that it was observational, non-randomised and, not blinded (but considered that blinded studies were now unlikely to be conducted), the short follow up period, possible selection bias, and imprecision with wide confidence intervals.\xa0</p><p>1.23.<span style=""font-size: 7pt;"">\xa0\xa0\xa0</span>The Committees noted a prospective three year SMArtCARE Registry-based observational longitudinal follow-up study that assessed improvements in walking distance during nusinersen treatment (<a href=""https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9881023/"" target=""_blank"">Pechmann et al. 2023;10(1):29-40</a>). The Committees noted that the study included adult as well as paediatric participants, all whom were walking independently at the start of the study. The Committees noted the mean age of SMA symptom onset was 11 years, and mean age at the start of treatment was 37 years. The Committees noted that 26% of adult participants experienced clinically meaningful improvement of equal to or more than 30 metres in the 6-minute walk time (6MWT) test at the last available visit (up to 38 months).</p><p>1.24.<span style=""font-size: 7pt;"">\xa0\xa0\xa0</span>The Committees also noted the following reviews:</p><p class=""ql-indent-1""><span style=""font-family: Symbol;"">·</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span><a href=""https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8515709/"" target=""_blank"">Coratti et </a><a href=""https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8515709/"" target=""_blank"" style=""color: windowtext;"">al</a><a href=""https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8515709/"" target=""_blank"">. Orphanet J Rare Dis. 2021;16(1):430</a></p><p class=""ql-indent-1""><span style=""font-family: Symbol;"">·</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span><a href=""https://pubmed.ncbi.nlm.nih.gov/35178673/"" target=""_blank"">Gavriilaki et al. Neurotherapeutics. 2022;19(2):464-75</a></p><p class=""ql-indent-1""><span style=""color: windowtext; font-family: Symbol;"">·</span><span style=""color: windowtext; font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span><a href=""https://pubmed.ncbi.nlm.nih.gov/35218574/"" target=""_blank"">Rad et al. Muscle Nerve. 2022;65(5):498-507</a></p><p class=""ql-indent-1""><span style=""font-family: Symbol;"">·</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span><a href=""https://www.ncbi.nlm.nih.gov/books/NBK566621/"" target=""_blank"">Janoudi et ak. Ottawa (ON): Canadian Agency for Drugs and Technologies in Health. 2020.</a></p><p>1.25<em>.</em><span style=""font-size: 7pt;"">\xa0\xa0\xa0</span>Committee noted results from <a href=""https://pubmed.ncbi.nlm.nih.gov/31019106/"" target=""_blank"">Darras et al. Neurology. 2019;92(21):e2492-e2506</a>, a phase 1b/2a study which followed 28 children with SMA, 18 of whom had type III disease. All motor outcomes improved over the 715 day extension arm of the study.\xa0</p><p>1.26.<span style=""font-size: 7pt;"">\xa0\xa0\xa0</span>The Committees considered that the evidence for nusinersen in the groups under consideration is limited to a small number of studies, but that further high quality evidence is unlikely due to the funding of SMA treatments internationally. </p><p><br></p><h4><span style=""font-family: Arial, sans-serif; font-size: 11pt;"">Risdiplam</span></h4><p>1.27.<span style=""font-size: 7pt;"">\xa0\xa0\xa0</span>The<em> </em>Committees noted that there are currently no published studies evaluating the efficacy and safety of risdiplam specifically in an adult population. However, the SUNFISH trial included individuals with SMA types II and III who were aged 2-25 years (median age 9) old at the time of randomisation (<a href=""https://pubmed.ncbi.nlm.nih.gov/34942136/"" target=""_blank"">Mercuri et al. Lancet neurol. 2022;21:42-52</a>). The Committees noted that 180 participants were included in the study, 22 of whom were aged 18-25 years at randomisation. The Committees noted that 67% of the study population had scoliosis and 25% had had spinal surgery; thus the Committees considered this group to have severely impacted motor function. The Committees noted that results were not stratified into type IIIa, b, or c.</p><p>1.28.<span style=""font-size: 7pt;"">\xa0\xa0\xa0</span>The Committees noted that in the 18–25-year age group, there was no significant improvement in motor function measure: -0.65 (-4.03 to 2.74), however a significant improvement in the revised upper limb module was observed: 1.74 (-1.06 to 4.53). </p><p>1.29.<span style=""font-size: 7pt;"">\xa0\xa0\xa0</span>Members considered that the improvements seen for this group represented clinically meaningful outcomes. </p><p>1.30.<span style=""font-size: 7pt;"">\xa0\xa0\xa0</span>Members considered that while the SUNFISH trial did not include stratified results for type IIIb and IIIc individuals, SMA is a spectrum of disease and so it is reasonable to extrapolate that these group would also receive benefit from treatment.</p><p>1.31.<span style=""font-size: 7pt;"">\xa0\xa0\xa0</span>The Committees considered an article describing the Clinical experience through Early Access Medicines Scheme (EAMs) Northern Ireland for risdiplam for the treatment of adults with SMA (<a href=""https://pubmed.ncbi.nlm.nih.gov/36382958/"" target=""_blank"">McCluskey et al. 2023;67(2):157-71</a>). The study included six participants with a mean age of 33.7 years, none of whom had received prior treatment with onasemnogene (due to age) or nusinersen (due to complex spinal anatomy). There was no change in RULM score or respiratory function. There was an Egan Kallifikation 2 (EK2) Mean change -4.5(95%CI -7.3- -1.7, p=0.009), and a quality-of-life measure (QOLM) Mean change of +10.7(95%CI 1.4-19.5, p=0.027). Patients reported a range of observed benefits including multiple motor improvements. All participants reported an overall improvement in strength, sense of wellbeing, and speech quality.</p><p><br></p><h4><span style=""font-family: Arial, sans-serif; font-size: 11pt;"">General</span></h4><p>1.32.<span style=""font-size: 7pt;"">\xa0\xa0\xa0</span>The Committees considered that where evidence was available for only one treatment (ie. risdiplam or nusinersen) within a patient group, that it was reasonable to assume that both treatments would provide the same or similar level of benefit within that group. The Committees noted that this was due to similar mechanisms of action, biological plausibility, and similar outcomes when studies in other subgroups. </p><p>1.33.<span style=""font-size: 7pt;"">\xa0\xa0\xa0</span>The Committees noted that after the age of 20 years, most of an individual with SMA’s motor neurons may be lost, and thus treatment with nusinersen or risdiplam would not be expected to regain lost function. By contrast, those treated early a greater proportion of motor neurons would be protected, with a resultant greater benefit. Members noted that there was limited available evidence to confirm that loss function cannot be regained with treatment. The Committees considered that for adults with SMA, while the published evidence suggests that treatment would not result in a significant improvement in motor function and other symptoms; the demonstrated maintenance of motor function provides a clinically meaningful outcome, which should not be underestimated.</p><p>1.34.<span style=""font-size: 7pt;"">\xa0\xa0\xa0</span>The Committees noted there was no published evidence which supported the use of nusinersen or risdiplam in individuals with adult-onset SMA (Type IV). </p><p>1.35.<span style=""font-size: 7pt;"">\xa0\xa0\xa0</span>Members considered that is the funding criteria relating to SMN2 copies were widened to allow for individuals to access treatment with up to 3 SMN2 copies, then most people who would later develop SMA symptoms would be diagnosed and treated symptomatically, however. Members considered that extension of the criteria to include 4 SMN2 copies may include individuals with milder phenotypes who have a reduced cost-benefit for treatment. Members commented it would be appropriate to have guidelines in place to ensure those who are identified as having 4 copies SMN2 copies through pre-symptomatic screening are monitored more closely for the development of symptoms.</p><h3><em>Suitability</em></h3><p>1.36.<span style=""font-size: 7pt;"">\xa0\xa0\xa0</span>The Committees noted that nusinersen is administered intrathecally by a health care professional. The Committees considered that administration of nusinersen is often complicated in individuals with severe scoliosis. Members considered that adults with SMA types II and III, particularly those who are non-ambulant may experience significant scoliosis and mobility problems, as well as previous orthopaedic surgery, and therefore those affected may require alternative interventions to administer the treatment (<a href=""https://pubmed.ncbi.nlm.nih.gov/35218574/"" target=""_blank"">Rad et al. Muscle Nerve. 2022;65(5):498-507</a><u>)</u>. The Committees considered that transport to a clinical setting for tri-annual infusions may be difficult for some due to the individuals’ ambulation status and potential distance from treatment centres and socioeconomic status. As such, the Committees considered risdiplam, as an oral treatment, would likely be a more suitable treatment and result in less inequity for non-ambulant adults with SMA.</p><p>1.37.<span style=""font-size: 7pt;"">\xa0\xa0\xa0</span>The Committee considered that due to the size of the risdiplam bottles, the oral liquid would not last long for adult patients. The Committee noted that a tablet form is currently being developed to overcome this problem.</p><h3><em>Cost and saving</em></h3><p>1.38.<span style=""font-size: 7pt;"">\xa0\xa0\xa0</span>The Committees noted that the administration costs associated with giving nusinersen by lumbar puncture were high in comparison with zero administration costs associated with the orally administered risdiplam.</p><p>1.39.<span style=""font-size: 7pt;"">\xa0\xa0\xa0</span>The Committees also considered that the benefit that could be obtained in people who were over 18 years of age at the time of treatment initiation was likely lower than that obtained for people starting treatment at the time of symptom onset (and far lower than that for people diagnosed and treated pre-symptomatically). However, the Committees considered the magnitude of treatment benefit highly uncertain in economic terms, and that while people with treatment may experience a less severe disease phenotype, advice from specialists treating people in this group would need to be obtained to ascertain the magnitude of benefit and a means of expressing and quantifying it in economic modelling.</p><h3><em>Summary for assessment</em></h3><p>1.40.<span style=""font-size: 7pt;"">\xa0\xa0\xa0</span>The <span style=""color: black;"">Advisory Committees considered that the below table summarises its interpretation of the most appropriate PICO (population, intervention, comparator, outcomes) information for nusinersen and risdiplam if they were to be funded in New Zealand for SMA in people who did not meet existing funding criteria. This PICO captures key clinical aspects of the proposal and may be used to frame any future economic assessment by Pharmac staff. This PICO is based on the Advisory Committees’ assessment at this time and may differ from that requested by the applicant. The PICO may change based on new information, additional clinical advice, or further analysis by Pharmac staff.</span></p><p><span style=""color: black;""><span class=""ql-cursor"">\ufeff</span></span><img src=""/apptracker/servlet/rtaImage?eid=a0POZ000009Dz0w&amp;feoid=00N2P000000YsIc&amp;refid=0EMOZ0000005tez"" alt=""image.png""></img></p>', 'Status_History__c': 'a13OZ000001LdUFYA0'}, 'change': None}]",Feb 2023,False,True
2,"<p>Following Clinical Advice, Pharmac staff considers the advice and the funding application under goes an assessment using our&nbsp;<a class=""external-link"" href=""https://www.pharmac.govt.nz/medicines/how-medicines-are-funded/factors-for-consideration/"" rel=""nofollow"">Factors for Consideration</a>&nbsp;framework and seeks additional information as required.</p>
<p>&nbsp;</p>
<p>Research and Economic analysis are undertaken.&nbsp; This focuses on the costs and benefits of a proposed course of action. Economics is based on three fundamental concepts that summarise the issues Pharmac faces daily:&nbsp;</p>
<ul>
<li>Scarcity &ndash; resources will always be insufficient to support all possible activities.</li>
<li>Choices &ndash; due to scarce resources, decisions must be made about how best to use them.</li>
<li>Opportunity cost &ndash; by choosing to use resources one way, we forgo other opportunities to use the same resources.</li>
</ul>
<p>&nbsp;</p>
<p>For further information on the purpose of, and techniques for, undertaking economic analysis in health care, please refer&nbsp;<a class=""external-link"" href=""https://www.pharmac.govt.nz/medicines/how-medicines-are-funded/economic-analysis/"" rel=""nofollow"">https://www.pharmac.govt.nz/medicines/how-medicines-are-funded/economic-analysis/</a></p>",2,Under Assessment,False,"[{'Summary': {'s': None, 'fs': None, 'change': None}, 'Published_Recommendation': {'s': None, 'fs': None, 'change': None}, 'Published_Discussion': {'s': None, 'fs': None, 'change': None}, 'Published_Application': {'s': None, 'fs': None, 'change': None}, 'PTAC_Comments': {'s': None, 'fs': None, 'change': None}, 'Outcome': {'s': None, 'fs': None, 'change': None}, 'Links': {'s': None, 'fs': None, 'change': None}, 'Formatted_Date': {'s': 'Dec 2023', 'fs': 'Dec 2023', 'change': None}, 'Event_Description': {'s': 'Working to compare options', 'fs': 'Working to compare options', 'change': None}, 'e': {'attributes': {'type': 'Application_Event__c', 'url': '/services/data/v65.0/sobjects/Application_Event__c/a0POZ000009Dz0x2AC'}, 'Id': 'a0POZ000009Dz0x2AC', 'Event_Date__c': '2023-12-13', 'Event_Description__c': 'Working to compare options', 'Stage__c': 'Under Assessment', 'Formatted_Date__c': 'Dec 2023', 'Status_History__c': 'a13OZ000004Yr63YAC'}, 'change': None}, {'Summary': {'s': None, 'fs': None, 'change': None}, 'Published_Recommendation': {'s': None, 'fs': None, 'change': None}, 'Published_Discussion': {'s': None, 'fs': None, 'change': None}, 'Published_Application': {'s': None, 'fs': None, 'change': None}, 'PTAC_Comments': {'s': None, 'fs': None, 'change': None}, 'Outcome': {'s': None, 'fs': None, 'change': None}, 'Links': {'s': None, 'fs': None, 'change': None}, 'Formatted_Date': {'s': 'Jun 2024', 'fs': 'Jun 2024', 'change': None}, 'Event_Description': {'s': 'Working to compare options', 'fs': 'Working to compare options', 'change': None}, 'e': {'attributes': {'type': 'Application_Event__c', 'url': '/services/data/v65.0/sobjects/Application_Event__c/a0POZ000009Dz0y2AC'}, 'Id': 'a0POZ000009Dz0y2AC', 'Event_Date__c': '2024-06-03', 'Event_Description__c': 'Working to compare options', 'Stage__c': 'Under Assessment', 'Formatted_Date__c': 'Jun 2024', 'Status_History__c': 'a13OZ00000AhUxzYAF'}, 'change': None}]",Dec 2023,False,True
3,"<p>Pharmac staff uses a prioritisation process to compare and rank funding options. Possible opportunities for new investment will always exceed the budget Pharmac has available; therefore, prioritisation is an intrinsic part of Pharmac’s decision-making process.</p>
<p>The relative ranking of options aims to support Pharmac&rsquo;s statutory objective &ldquo;to secure for eligible people in need of pharmaceuticals, the best health outcomes that are reasonably achievable from pharmaceutical treatment and from within the amount of funding provided&rdquo;.</p>
<p>A funding application or proposal is considered ready for prioritisation when sufficient information is available to permit it to be reviewed against Pharmac's Factors for Consideration and to inform a comparison with other possible investment decisions.</p>
<p>There is no guarantee when or if a ranked medicine will be funded.&nbsp;&nbsp;<a class=""external-link"" href=""https://www.pharmac.govt.nz/medicines/how-medicines-are-funded/prioritisation/"" rel=""nofollow"">https://www.pharmac.govt.nz/medicines/how-medicines-are-funded/prioritisation/</a></p>",3,Options Compared,False,"[{'Summary': {'s': None, 'fs': None, 'change': None}, 'Published_Recommendation': {'s': None, 'fs': None, 'change': None}, 'Published_Discussion': {'s': None, 'fs': None, 'change': None}, 'Published_Application': {'s': None, 'fs': None, 'change': None}, 'PTAC_Comments': {'s': None, 'fs': None, 'change': None}, 'Outcome': {'s': None, 'fs': None, 'change': None}, 'Links': {'s': None, 'fs': None, 'change': None}, 'Formatted_Date': {'s': 'Jun 2024', 'fs': 'Jun 2024', 'change': None}, 'Event_Description': {'s': 'The relative ranking of the pharmaceutical application has been completed.', 'fs': 'The relative ranking of the pharmaceutical application has been completed.', 'change': None}, 'e': {'attributes': {'type': 'Application_Event__c', 'url': '/services/data/v65.0/sobjects/Application_Event__c/a0POZ000009Dz0z2AC'}, 'Id': 'a0POZ000009Dz0z2AC', 'Event_Date__c': '2024-06-07', 'Event_Description__c': 'The relative ranking of the pharmaceutical application has been completed.', 'Stage__c': 'Options Compared', 'Formatted_Date__c': 'Jun 2024', 'Status_History__c': 'a13OZ00000ArK4jYAF'}, 'change': None}]",Jun 2024,False,True
4,"<p>Pharmac is consulting on a proposal to either approve or decline the application.&nbsp;We seek the views of all people who have an interest in our proposals, or who may be affected by them, to obtain feedback on our proposed approaches.</p>
<p><a class=""external-link"" href=""https://www.pharmac.govt.nz/medicines/how-medicines-are-funded/having-your-say/"" rel=""nofollow"">https://www.pharmac.govt.nz/medicines/how-medicines-are-funded/having-your-say/</a></p>",4,Under Consultation,False,,,False,False
5,"<p>Following the consultation process, Pharmac staff considers the feedback and identifies any additional information required as part of a gap analysis.&nbsp; The proposal may require further clinical advice, research, and assessment.</p>",5,Reviewing Consultation Feedback,False,,,False,False
6,"<p>We refer to our decisions about whether and how particular pharmaceuticals are publicly-funded, as &ldquo;funding decisions&rdquo;.</p>
<p>We consider and assess all funding decisions using the&nbsp;<a class=""external-link"" href=""https://www.pharmac.govt.nz/about/operating-policies-and-procedures/#factorsfc"" rel=""nofollow"">Factors for Consideration</a>. When we do so, we carefully evaluate clinical and other evidence for the benefits and suitability of a proposal, and to identify and understand the people who will be affected by it.</p>
<p>While our main task is to allocate pharmaceutical funding, we consider the benefits and costs across the whole health system now and with a long-term focus, including the effects for hospitals and primary care, and consider direct costs to patients as well as to all health sector budgets.</p>
<p>Final funding decisions are made by the Pharmac Board or delegated to senior Pharmac staff as required by the Board.</p>
<p>&nbsp;</p>",6,Decision,True,,,False,False
